Seol, Hee Yun
Hong, Kyung Soo
Jang, Jong Geol
Moon, Seong Mi
Kim, Sun-Hyung
Cho, Jun Yeun
Yang, Bumhee
Kim, Seonok
Choi, Chang-Min
Ji, Wonjun
Ahn, June Hong
Funding for this research was provided by:
Korean Association for the Study of Targeted Therapy (KASTT) affiliated with Korean Association for Lung Cancer (KASTT-20230211)
Article History
Received: 11 April 2024
Accepted: 16 May 2024
First Online: 17 May 2024
Declarations
:
: The REST trial will be conducted in accordance with the principles of Good Clinical Practice and the tenets of the Declaration of Helsinki. The Institutional Review Board of each participating institution have already approved the study protocol: Yeungnam University Hospital (YUMC 2023–12–017), Asan Medical Center (S2023–2655), Pusan National University Yangsan Hospital (11–2023–024), and Chungbuk National University Hospital (2023–11–003–003). Informed consent will be obtained from all participants. The study is registered at ClinicalTrials.gov (NCT06275594).
: Not applicable.
: The authors declare no competing interests.